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Background: In HIV-1-infected patients a long lasting CD4+ cell decline influences the host-EBV balance and thereby
increases the risk for EBV related malignancies. In spite of a world-wide access to combination antiretroviral therapy
(cART) there are still a considerable number of HIV-1-infected patients who will develop severe immunodeficiency.
These undiagnosed HIV-1 infected patients, so called late testers, demonstrate an increased lymphoma risk, compared
to patients diagnosed early. Consecutive individual screening for EBV DNA-load in late testers might be a useful
predictor of emerging EBV-malignancy.
Methods: Patient biopsies and ascites were analyzed morphologically, by immuncyto-histochemistry and in-situ
hybridization. Viral DNA and RNA load were quantified by PCR. Cell lines from primary tumor and from ascites, were
established in vitro and further analyzed.
Result: We here report on a case of EBV-positive lymphoma in an AIDS patient, first presenting with pleural effusion
and ascites and was thus initially considered a primary effusion lymphoma (PEL) but was later diagnosed as a
plasmablastic lymphoma (PBL). The patient had responded to cART with undetectable HIV-RNA and increased CD4 cell
count one year prior to lymphoma presentation. At the time of lymphoma diagnosis the HIV-RNA values were <50
RNA-copies per mL blood (undetectable) and the CD4-positive cell count 170 ×106/L. The lymphoma was CD45-
negative and weakly CD22- and CD30-positive. The patient had a history of Kaposi sarcoma and HHV-8 seropositivity.
The lymphoma biopsies, and three cell lines derived on different occasions from the tumor cell effusion, were all EBV-
positive but HHV-8 negative.
A noticeable EBV-DNA load decline was observed during the remission of the lymphoma following CHOP-therapy. The
EBV-DNA load increased dramatically at the time of recurrence.
Conclusion: EBV DNA load might be useful in monitoring the effect of lymphoma treatment as well as in estimating
the risk of EBV-associated lymphoma in HIV-1 infected patients with pronounced immunosuppression.
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EBV infects the vast majority of humans and resides la-
tently in B-cells. The virus carries genes that can induce
and maintain mature B cell growth. In immunocom-
promised post-transplant and HIV-infected patients the
virus may cause lymphoproliferative or malignant diseases.
Although EBV negative lymphoid malignancies have been
described in HIV-infected persons EBV has a strong asso-
ciation with a wide range of B-cell lymphomas in HIV-
carriers including Burkitt’s lymphoma (BL), Hodgkin
lymphoma and Diffuse Large B-cell lymphomas [1].
Plasmablastic lymphoma (PBL) is a rare aggressive
subtype of non-Hodgkin lymphoma (NHL) most com-
monly localized to mucosal tissues such as the oral cav-
ity, but may also be manifest in other organs such as
liver, breast or bone [2]. Morphologically and immuno-
phenotypically PBL have some similarities to primary
effusion lymphomas (PEL) and both lymphomas are
EBV-positive and associated with immunodeficiency,
most frequently due to HIV-1 infection. Body cavity effu-
sion to pleura or abdomen, that is the hallmark of PEL, is
much less frequently seen in PBL. Moreover, PEL in virtu-
ally all cases is HHV-8-positive. In contrast PBL is rarely
HHV-8 positive [3].
Furthermore, PBL is CD45-negative, while PEL is
CD45-positive. Both PBL and PEL display markers asso-
ciated with plasma cell differentiation such as CD38 and
CD138 and usually express cytoplasmic immunoglobulin
and may be variably positive for CD30. Although most
cases of PBL occur in AIDS-patients with profound im-





























































Figure 1 Schematic presentation of patient HIV-1 disease related man
histopathologic analysis of Figures 2, 3, 4 and 5 are shown. SPIBL I, II, III: tum
three occasions.In the era of modern combination antiretroviral ther-
apy (cART) there has been an impressive reduction of
AIDS-related opportunistic infections and lymphomas.
However, HIV-1 patients still suffer an increased risk for
NHL [9] and the risk for development of NHL might be
considerable in patients with a late diagnosis of HIV- in-
fection and with severe immune dysfunction – so-called
late testers [10,11]. As HIV-1 infection induces a new viral
set point between host and EBV [12] several immune
modulating factors e.g. CMV, bacterial translocation [13]
or even vaccination [14] might trigger lymphoma genesis.
Results
Clinical report
When the patient was diagnosed with HIV-1 the CD4+
cell count was 170 × 106/L. In a malignancy assessment
the same year endoscopic biopsies were taken from the
gut mucosa. By routine histopathological analysis the bi-
opsies showed signs of chronic inflammation and macro-
phage infiltration, but no lymphoma. Bone marrow
aspiration was also performed with May-Grunewald
stained smears showing immature cells of the myeloid
series and many lymphoid cells (44%), including cells of
lymphoplasmocytoid/plasmacell type. Staining for kappa
and lambda light chains gave no evidence for clonal
B-cell proliferation. The findings were suggested to
represent a polyclonal B-cell hyperplasia without sus-
picion of lymphoma.
Oral hairy leukoplakia was diagnosed early the year
after HIV-diagnosis and the same year the patient devel-
oped hemolytic anaemia (Figure 1). The anaemia re-









































ifestations. Important clinical manifestations and time point of
or tissue and ascites derived cell lines were established on
Figure 2 Cytological examination of cells from abdominal
ascitic fluid. Stained with Giemsa.
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By the end of the second year after diagnosis of HIV in-
fection he contracted hemiparesis and a CT scan showed
a contrast enhancing lesion in the parietal left brain
hemisphere, suggestive of toxoplasmosis infection. The
patient improved on treatment with anti toxoplasmosis
drugs and continued this suppressive therapy.
In December the second year antiretroviral treatment
with azidothymidine (AZT) was initiated, and shortly
thereafter a conjunctival Kaposi lesion was removed. In
February the following year (year 3; Figure 1) the patient
had a CD4+ cell count of 30 × 106/L, and CMV-retinitis
was diagnosed and treated with altering foscarnet and
ganciclovir. During the fourth year HIV-RNA values in-
creased to 65 000/mL prompting a change in the anti-
retroviral treatment to AZT and didanosine. Second half
of fourth year cART was introduced (AZT, lamivudine,
and indinavir). After cART introduction, including a
protease inhibitor, HIV-RNA was <500/mL, and re-
mained undetectable during the following two years.
The patients CD4 cell count went from 30 × 106/L in
second half of year two after HIV-1 diagnosis to 190 ×
106/L after introduction of cART year four. The sup-
pressive CMV-treatment was withdrawn the same year
(year 4).
Soon after withdrawal of CMV treatment the patient de-
veloped night sweats and elevated lactatdehydrogenase
(LD), and one month later ascites. CT scan revealed a
mass in the gastric wall and pleural effusion. An initial
cytological analysis of the effusion suggested a primary ef-
fusion lymphoma (PEL). A biopsy from the tumor in the
gastric wall confirmed the presence of an EBV-positive
Non-Hodgkin lymphoma with immunoblastic features
considered to be a manifestation of PEL.
After diagnosis of the lymphoma cytostatic treatment
with cyclophosphamide, hydroxydaunorubicin (Doxo-
rubicin), vincristine (Oncovin), prednisolone (CHOP),
and intrathecal methotrexate was initiated and the asci-
tes disappeared within four days. At the time of lymph-
oma treatment Rituximab was not yet approved and was
therefore not a treatment option. The patient continued
with cART and suppressive toxoplasmosis treatment.
The CHOP treatment was repeated every 3rd week
and the patient completed six treatment cycles in
total. Before every CHOP treatment blood was drawn
for EBV-DNA analysis. EBV-load was also measured
on three occasions the month after completing CHOP
treatment. The remission of the tumor mass of the
gastric wall was confirmed with a CT-scan and the
patient did clinically well. Then, one month after
the final CHOP course, ascites reappeared together
with pleural effusion. Reintroduced cytostatic treat-
ment now only had marginal effect on the lymphoma.
Pleural effusions were evacuated twice. The patientdied four and a half years after HIV-1 diagnosis due
to progression of the lymphoma.
At autopsy lymphoma manifestations were observed
in spleen, liver, lymphoid organs and lymphomatous
dissemination to pleura and peritoneal cavity. A small
cerebral mass in globus pallidus was also found, but
this was not further analyzed to rule out lymphomatous
spread to the central nervous system lymphoma or a le-
sion related to the patient’s earlier diagnosed cerebral
toxoplasmosis.
Morphologic, immunohistochemical and flow cytometric
analysis
Retrospective in situ hybridization of the patient’s early
Kaposi manifestation did show EBER-expression in some
(probably lymphatic) cells.
When the patient presented with a gastric tumor and
ascitic and pleural effusions, cytological examination of
the ascitic fluid showed a population of dispersed large
blastic cells with a high frequency of mitoses and partly
vacuolated dark blue cytoplasm. The tumor cells were
morphologically highly reminiscent of blastic lymphoid
cells, with features of immunoblastic plasmablastic dif-
ferentiation (Figure 2). By immunochemical staining of
cytospins from the ascitic fluid of tumor cells were nega-
tive for CD45, as well as for CD19 and CD79A. The
tumor cells were only weakly positive for CD22 and
CD30, but strongly positive for CD4 (Figure 3). By im-
munocytochemistry strong staining for EBV-LMP1 was
also seen in some of the blastic tumor cells. Small lym-
phocytes positive for CD3, CD5 and CD8 were seen at
low frequency both by flowcytometry (around 10%) and
by immunocytochemistry. A cell line derived from the
effusion showed a lymphoblastoid appearance.
A trans-abdominal core biopsy was subsequently
obtained from the extra nodal tumor in the gastric wall,
Figure 3 Immunohistochemistry of cytospin from abdominal ascites. Staining for CD45 (A), for CD19 (B), CD22 (C) CD30 (D), CD4 (E) and CD3 (F).
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ology and molecular analysis. The routine hematoxylin-
eosin (H-E) staining showed an infiltration of a large cell
malignant lymphoma with immunoblastic/plasmablastic
features, but without any mucosal component or lymph
node structures in the specimen (Figure 4). The morph-
ology was considered compatible with the findings in
cytological specimens from the ascitic fluid and thus ini-
tially suggested to be a solid tumor component of a PEL.
However, later investigations showed negative results for
HHV8 LANA1 antigen staining. Additional immun-
histochemical stainings revealed negativity for CD45 and
CD20, but a clonal cytoplasmic Kappa staining (Figure 4).
Thus, the lymphoma was reconsidered to better fulfill
the criteria for a PBL with pleural effusion and ascites
already at diagnosis than a PEL. Further immunohisto-
chemistry revealed a weak positive staining for CD74,Figure 4 Immunohistochemistry staining of tissue sections of a core bio
eosin (A) and Giemsa staining (B), CD20 (C), CD138 (D), lambda (E) and kappthe HLA-DR associated invariant chain, negative stain-
ing for cytokeratins, the melanoma antigen HMB45 and
CD34. Tumor cell staining for EBNA 2 was negative,
whereas LMP1 was strongly positive in a few cells. Ap-
proximately 90% of the tumor cells were positive for
Ki67 (data not shown).
Additional analysis was performed on autopsy mater-
ial. Immunohistochemical analysis on sections was posi-
tive for CD43 and CD138 (syndecan 1; Figure 5) CD38
and Mum1. In-situ hybridization for nuclear EBV RNA
(EBER) was positive, while HHV-8, CD20, PAX5 and
CD45 all were negative by immunohistochemistry (data
not shown).
This case illustrates a diagnostic dilemma. The initial
finding was that of a blastic EBV-positive lymphoma pri-
marily detected in effusions, lacking obvious B- and T-cell
markers except CD4 but showing evidence of plasma cellpsy of the abdominal tumor from ventricular wall. Hematoxylin-
a (F).
Figure 5 Immunohistochemistry of mediastinal tumor material post mortem. Stained with antibodies to CD20 (A), CD45 (B), HHV-8 (C),
and in situ probing for EBV EBER (D), CD43 (E), leukocyte membrane antigen and CD138 (syndecan 1; F).
Friis et al. Infectious Agents and Cancer 2013, 8:28 Page 5 of 9
http://www.infectagentscancer.com/content/8/1/28differentiation as indicated by positivity for CD38 and
CD138. Based on this information a diagnosis of PEL was
originally suggested. However after further investigations
showing clonal kappa positivity but HHV8 and CD45
negativity the case was finally considered to better fulfill-
ing the criteria for a PBL.
Although effusions to the pleura and abdomen are rare
features of PBL, they are the hallmarks of PEL. Con-
versely extra-nodal solid organ involvement, a feature of
PBL is rarely seen in PEL, thus emphasizing the diagnos-
tic dilemma.
The fact that the patient's lymphoma was CD45-
negative, HHV-8-negative and EBV-positive became de-
cisive for the final classification.
EBV- DNA analysis
A noticeable decline of EBV-DNA load was observed
during remission of the lymphoma following CHOP-
therapy. The EBV-DNA load then increased dramatically
at the time of recurrence (Figure 6, Table 1).
Cell lines
Cell-lines were successfully derived from the patient
lymphomas on three different occasions. One was
established from ascites infusion during the first mani-
festation before therapy (SPIBL-I; second half of year 4;
Figure 1) and two from pleural effusions after the relapse(SPIBL-II & III; late first half of year 5; Figure 1). These
cell lines were characterized for EB-viral gene-expression
and presence of EBV-, HHV-8- and HIV-1-genomes,
morphology, karyotype and immunoglobulin-gene
rearrangement (Tables 1 & 2). They were all of B-
lymphocyte origin expressing cell surface immuno-
globulins. They carried EBV-DNA, but no HIV- or HHV-
8-genomes were detected. Most conspicuously their
phenotypes were distinctly different. SPIBL-I showed
morphologic features of a lymphoblastoid cell line (LCL),
growing in clumps and with irregular cell shapes. SPIBL-II
and III showed many features of Burkitt-lymphoma de-
rived cell lines, with rounded cells not forming clumps.
Moreover the karyotype of SPIBL-I, the LCL-like cell
was close to diploid, while SPIBL-II and III were close
to tetraploid with a lot of aneuploidy, with several
marker chromosomes: chromosome number 1, 3, 6, 7,
11, and 15.
The EBV gene expression patterns were consistent
with these observations, SPIBL-I showed a latency III
pattern and SPIBL-II and III both showed latency I pat-
tern, expressing only EBNA 1, but no EBNA 2.
Clonal analysis was performed using the rearrange-
ment of immunoglobulin heavy chain genes. This ana-
lysis showed that all three cell lines are monoclonal, but
that SPIBL-I have a different clonal origin (one restric-
tion fragments at 87–92 kD) than SPIBL-II and III (one
Figure 6 EBV genome load, HIV-1 RNA titer, treatment events and relapse. Time line illustration of measured parameters, treatment events
and clinical findings. Time 0 is equal to first blood sampling for HIV-1 RNA analysis and EBV genome load measurement. HIV-1 RNA titers are
illustrated with rhombic symbol. EBV genome load development is illustrated by solid line, and CHOP treatment events indicated by x's.
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The clinical features of this patient’s lymphoma manifes-
tations were at the time of diagnosis consistent with pri-
mary effusion lymphoma (PEL), with ascitic and pleural
effusions. Gene expression profile analysis of PEL has
suggested a plasmablastic derivation in common with
PBL [15]. Nevertheless the biopsies and the derived cell
lines were HHV-8 negative while they expressed EBV
genes. In the recent WHO classification of malignant
lymphomas [2] the plasmablastic type of lymphoma
(PBL) was distinguished from other types of aggressive
B-cell derived lymphomas. This classification, which is
based on the combined clinical, morphological, and gen-
etic and phenotypic features considers the PBL as an en-
tity distinct from PEL and other immunodeficiency
associated lymphomas. The key distinguishing character-
istics of PBL are positivity for EBV, plasmacell-markers
CD38 and CD138 and clonal cytoplasmic immunoglobu-
lin but negativity for CD45 and HHV-8. In spite of a
PEL-like presentation our current case fulfills the criteria
above for a PBL.
HIV-associated PBL is considered as a very aggressive
lymphoma, with a poor prognosis also in the era of
cART [16].
As far as could be analyzed on the autopsy material
this lymphoma had histopathological and phenotypical
features that were similar at first diagnosis and after re-
currence. At relapse the lymphoma was spread both to
extra-nodal sites and reappearing in effusions.The CD4 expression on the PBL cells was unexpected,
but has been seen in other cases, as has recently been
reviewed [17]. Moreover, in a recent publication Goto H
et al. [18] describes the establishment of a CD4-positive
cell line from an HIV-patient with PEL making our find-
ing less conspicuously unique.
The cell lines derived from the biopsies taken before
and after recurrence were distinctly different. Cell lines
from the early lymphoma had a lymphoblastoid cell line
feature, i.e. similar to immunoblastic lymphoma. The
cell lines derived from pleural effusion at recurrence
were BL like, but did not have the t(8;14) translocation





Source HIV-1 HHV-8 EBV Ig-rearrangement* Ig-expression Phenotype Karyotype/aberration
in chromosome no
I 971001 Ascites - - +/ latency III + 87-92kD + kappa LCL Diploid
II 980526 Pleura - - +/ latency I + 87–92 kD/108 kD + kappa BL Chr 1, 3, 6, 7, 11 and 15.
III 980626 Pleura - - +/ latency I + 87-92kD/108 kD + kappa BL Chr 1, 3, 6, 7, 11 and 15.
* clonal rearranged Ig-heavy chain locus fragments detected by PCR.
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which altogether would be compatible with the
plasmablastic phenotype, also suggested by other
markers on the cell lines. The cell lines were also differ-
ent from reported HHV-8-positive PEL lines, which
regularly do not express any immunoglobulin [3].
From clonal analysis of immunoglobulin-rearrangement
we can conclude that the cell lines seem to share one
marker of rearrangement of the heavy chain locus, while
another marker is seen in addition to the BL like/PBL-cell
lines. This might indicate that they represent clonal pro-
gression from the original lymphoma precursor cell, al-
though it is more likely that they are derived from
different clones. SPIBL-I could also be a spontaneous
lymphoblastoid cell line derived from latently EBV
infected cells not related to the tumor, although its origin
from the ascitic effusion would be compatible with a
tumor origin.
At the time of progression the HIV-RNA was non-
detectable and CD4+ cell count had increased, although
not to an acceptable level. A persevering decreased CD4+
cell count can be reflected in the lack of EBV control [19].
A long lasting CD4 cell decline together with increased
EBV load seems to be an indicator of lymphoma risk. In
spite of the introduction of cART to patients with such
durable CD4+ cell depletion, the normalization of CD4+
cell number and function takes a considerable period of
time [20]. EBV-DNA load is not a direct indicator of
lymphomagenesis [21] in HIV-1 infected patients although
they may show elevated EBV-DNA values prior to the
lymphoma diagnosis [22].
Our finding of an EBV-DNA decline and persistence
of low EBV-DNA loads clearly reflects the cytostatic
treatment effect on the lymphoma. The subsequent, pro-
nounced EBV-DNA increase preceding the lymphoma
relapse suggests a value of EBV monitoring in treatment
as well as follow up of EBV-positive lymphomas. This in-
dicates the use of EBV-DNA load as a marker for recur-
rence as well as a treatment effect marker. The use of
EBV-DNA load has also been clearly shown in the as-
sessment of risk for EBV-positive PTLD in transplanted
patients [23-25].
In HIV-1-infected patients a long lasting decline of
CD4+ cells will disrupt the host-EBV balance and in-
crease the risk for EBV related malignancy. In spite of
the worldwide access to cART and awareness of HIV-1there are still a considerable number of undiagnosed
HIV-1-infected individuals, who will have developed se-
vere immune deficiency at the time of HIV diagnosis.
When initiating cART treatment at the time of HIV-
diagnosis in this patient group (so called “late testers”),
repeated analysis of EBV- could be of value in estimating
the lymphoma risk.
Conclusion
In this rare PBL with effusion our finding of EBV-DNA
decline and persistence of low EBV-DNA load reflects
the positive effect of cytostatic treatment on the lymph-
oma. This finding together with a pronounced EBV-DNA
increase preceding the lymphoma relapse demonstrates
the value of EBV monitoring in treatment of EBV-positive
lymphomas in AIDS-patients. The result indicates the
usefulness of EBV-DNA load as a marker for recurrence
and treatment effects. EBV DNA-load might also be use-
ful as an indicator of lymphoma risk in HIV-infected pa-




A 36 year old homosexual man was diagnosed with HIV-1
in 1993. Two years later a Kaposi conjunctival lesion was
removed (Figure 1). The second year, with a CD4+ cell
count of 30 × 106/L, antiretroviral treatment was initiated
and in year three the patient began with cART. In the
middle of year four the patient was diagnosed with a
lymphoma. The lymphoma went into remission after cyto-
static treatment, but recurred three months later with
massive pleural effusion. The patient died in middle of
year five. Biopsies were taken from the gut the first year,
four years prior to the lymphoma diagnosis and from the
developed lymphoma on three occasions in year five.
Morphologic, immunohistochemical and flow cytometric
analysis
The biopsies and autopsy specimens were fixed in neu-
tral buffered formalin and processed for routine histo-
pathological analysis by histochemical staining of
paraffin sections.
Immunohisto- and cytochemistry was done according
to standardized procedures and with reagent kits using
manual and automated processes (Techmate 500 plus
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munocytochemistry an alkaline phosphatase chromogenic
substrate was used, whereas for immunohistochemistry a
peroxidase-based detection system was employed ac-
cording to the manual (Dako ChemMate Detection kits;
Peroxidase/diaminobenzine and a Rabbit/Mouse poly-
linker). Pre-treatment protocols for antigen demasking on
paraffin sections were used according to standard proced-
ure for each antibody.
Flow cytometry was performed with a Becton-
Dickinson analyser (Becton-Dickinson).
Establishment and culture of cell lines
Tissue biopsy materials, aspiration from ascitic and
pleural effusions, were collected upon surgical excision
or aspiration from the patient, stored in sterile 0.9%
NaCl and were set up within 4 hours for tissue culture.
Biopsy material was minced with scissors and forceps
and passed through a metal wire mesh 3–4 times. The
cell suspension thus generated was set up in 12-well
microplates with RPMI 1640 and antibiotics. The cul-
tures were followed regularly by microscopical examin-
ation and fed by replacing some half the culture medium
once every 4–7 days in the beginning. Cells from the
first biopsy occasion were transferred to microplates
with irradiated fibroblast feeder layer. After one-two
weeks clumps or loose aggregates of cells were detected
and they were explanted in five mL Falcon plastic tubes
on feeder layers after 2–3 months, and subsequently
upon expansion of the cells to 25 mL Falcon bottles
(spontaneous immunoblastoid cell line, SPIBL I). The
second and third attempts to establish cell lines (SPIBL
II and III) from the relapsed pleura effusions were very
different and cells grew out much faster than on the first
attempt, already 1–2 weeks after in vitro explanation.
The established cell lines were used for characterization
and also stored away by freezing.
Phenotypic analysis of cell lines
The cell lines were analyzed by standard light microscopy.
Analysis of karyotypes
Chromosomes in the cell lines were analyzed by making
metaphase plates and stained for Giemsa-banding, ac-
cording to Zech et al. [26].
Analysis of immunoglobulin-gene rearrangement
Cellular DNA was analyzed using a PCR method [27].
DNA and RNA quantification
EBV-PCR from blood analysis and statistics were per-
formed as previously reported by Friis et al. [19]. EBV
was measured in purified B-cells to get comparable
values between time points, avoiding the confounder ofvariation in B-cell proportion of as well as the effect of B-
cell variation over time in AIDS patients [19]. Quantifica-
tion of HIV-1 RNA levels in blood were determined by
using commercial kits NASBA (BioMérieux) or Amplicor
HIV-1 monitor test (version 2.0, Roche Diagnostic Systems
Inc.) and performed as recommended by manufacturer.
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